Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics

Journal of Immunological Methods

Volumn 357, Issue 1-2, 2010, Pages 10-16

  Tatarewicz, Suzanna ^a   Miller, Jill M ^a   Swanson, Steven J ^a   Moxness, Michael S ^a  

^a AMGEN INC   (United States)

Author keywords

Aggregation; HAHA; Immunoassay; Immunogenicity; Interference; Rheumatoid Arthritis; Rheumatoid Factor; Therapeutic monoclonal antibody

Indexed keywords

ANTIBODY CONJUGATE; BIOTIN CONJUGATE; BUFFER; IMMUNOGLOBULIN ANTIBODY; MONOCLONAL ANTIBODY; RHEUMATOID FACTOR; RUTHENIUM CONJUGATE; SORBITOL; UNCLASSIFIED DRUG; ANTIBODY; RUTHENIUM;

ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG STABILITY; DRUG STORAGE; ELECTROCHEMOLUMINESCENT; GEL PERMEATION CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; MOLECULAR WEIGHT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TEMPERATURE; BLOOD; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; METHODOLOGY; SENSITIVITY AND SPECIFICITY;

ANTIBODIES; ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMMUNOASSAY; RHEUMATOID FACTOR; RUTHENIUM; SENSITIVITY AND SPECIFICITY;

EID: 77952514487     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.03.012     Document Type: Article

References (22)

1. Artandi S.E., Calame K., Morrison S.L., Bonagura V.R. Monoclonal IgM rheumatoid factors bind IgG at a discontinuous epitope comprised of amino acid loops from heavy-chain constant region domains 2 and 3. Proc. Nat. Acad. Sci. 1992, 89:94.
2. Bartelds G.M., Wolbink G.J., Stapel S., Aarden L., Lems W.F., Dijkmans B.A., Nurmohamed M.T. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann. Rheum. Disord. 2006, 65(9):1249.
3. Dorner T., Egerer K., Feist E., Burmester G.R. Rheumatoid factor revisited. Curr. Opin. Rheumatol. 2004, 16:246.
4. Edelman G.M., Kunkel H.G., Franklin E.C. Interaction of the rheumatoid factor with antigen-antibody complexes and aggregated gamma globulin. J. Exp. Med. 1958, 108(1):105.
5. Hansonn U. Aggregation of human immunoglobulin G upon freezing. Acta Chem. Scand. 1968, 22:483.
6. Hay F.C., Jones M.G., Bond A., Soltys A.J. Rheumatoid factors and complex formation. The role of light-chain framework. Clin. Orthop. 1991, 265:54. April.
7. Hay F.C., Soltys A.J., Tribbick G., Geysen H.M. Framework peptides from ΚIIIb rheumatoid factor light chains with binding activity for aggregated IgG. Eur. J. Immunol. 1991, 21:1837.
8. Hennig C., Rink L., Fagin U., Jabs W.J., Kirchner H. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J. Immunol. Methods 2000, 235:71.
9. Jones A.M., Honour J.W. Unusual results from immunoassays and the role of the clinical endocrinologist. Clin. Endocrinol. 2006, 64(3):234.
10. Larsson A., Karlsson-Parra A., Sjöquist J. Use of chicken antibodies in enzyme immunoassays to avoid interference by rheumatoid factors. Clin. Chem. 1991, 37(3):411.
11. Moxness M., Tatarewicz S., Weeraratne D., Murakami N., Wullner D., Mytych D., Jawa V., Koren E., Swanson S.J. Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin. Chem. 2005, 51:1983.
12. Naredella F.A., Teller D.C., Mannik M. Studies on the antigenic determinants in the self-association of IgG rheumatoid factor. J. Exp. Med. 1981, 154:112.
13. Piedmonte D.M., Summers C., McAuley A., Karamujic L., Ratnaswamy R. Sorbitol crystallization can lead to protein aggregation in frozen protein formulations. Pharm. Res. 2007, 24:136.
14. Ritter G., Cohen L.S., Williams C., Richards E.C., Old L.J., Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res. 2001, 61:6851.
15. Roosnek E., Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J. Exp. Med. 1991, 173:487.
16. Selby C. Interference in immunoassay. Ann. Clin. Biochem. 1999, 36:704.
17. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L.A., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48(5):1267.
18. Soltys A.J., Hay F.C., Bond A., Axford J.S., Jones M.G., Randen I.R., Thompson K.M., Natvig J.B. The binding of synovial tissue derived human monoclonal Immnoglobulin M rheumatoid factor to Immunoglobulin G preparations of differing galactose content. Scand. J. Immunol. 1994, 40:135.
19. Soltys A.J., Bond A., Westwood O.M., Hay F.C. The effects of altered glycosylation of IgG on rheumatoid factor-binding and immune complex formation. Adv. Exp. Med. Biol. 1995, 376:155.
20. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 2005, 289(1-2):1.
21. Weber T.H., Kapyaho K.I., Tanner P. Endogenous interference in immunoassays in clinical chemistry. A review. Scand. J. Clin. Lab. Invest Suppl. 1990, 201:77.
22. Westwood O.M.R., Nelson P.N., Hay F.C. Rheumatoid factors: what's new?. Rheumatology 2006, 45:379.